Wacker Biotech and RNAV8 Bio have formed a strategic alliance to advance mRNA-based therapies. The partnership combines Wacker’s biopharma manufacturing expertise with RNAV8’s mRNA engineering capabilities. Focus is placed on…
Wacker Biotech and RNAV8 Bio have formed a strategic partnership to advance mRNA therapeutics. Wacker Biotech brings its expertise in microbial fermentation, processing up to 650 liters of material, to…
Wacker Biotech partners with RNAV8 Bio to advance mRNA-based therapies, enhancing the biopharmaceutical landscape. The collaboration leverages Wacker's expertise in pDNA, mRNA production, and LNP formulation with RNAV8's mRNA engineering,…
The joint venture between Wacker Biotech and RNAV8 Bio is advancing mRNA-based therapies. Focus is on optimizing mRNA untranslated regions (UTRs) to enhance drug stability and efficacy. Wacker Biotech's mRNA…